Streetbeat News

Analyst Ratings

ZM

RBC Capital analyst Rishi Jaluria has reiterated an 'Outperform' rating on Zoom Video Comms (NASDAQ:ZM) and maintained a $95 price target.

Portfolio Pulse from Benzinga Newsdesk

October 12, 2023 | 4:55 pm

REGN

RBC Capital analyst Brian Abrahams has maintained a 'Sector Perform' rating on Regeneron Pharmaceuticals (NASDAQ:REGN) and raised the price target from $833 to $847.

Portfolio Pulse from Benzinga Newsdesk

October 12, 2023 | 4:53 pm

XOM

RBC Capital analyst Biraj Borkhataria has reiterated a 'Sector Perform' rating on Exxon Mobil (NYSE:XOM) and maintained a price target of $120.

Portfolio Pulse from Benzinga Newsdesk

October 12, 2023 | 4:50 pm

CHD

Barclays analyst Lauren Lieberman maintains an Underweight rating on Church & Dwight Co (NYSE:CHD) and lowers the price target from $82 to $76.

Portfolio Pulse from Benzinga Newsdesk

October 12, 2023 | 4:40 pm

BLDR

Barclays analyst Matthew Bouley maintains an Overweight rating on Builders FirstSource (NYSE:BLDR) but lowers the price target from $200 to $175.

Portfolio Pulse from Benzinga Newsdesk

October 12, 2023 | 4:39 pm

BRBR

Barclays analyst Lauren Lieberman maintains an Overweight rating on BellRing Brands (NYSE:BRBR) and raises the price target from $43 to $47.

Portfolio Pulse from Benzinga Newsdesk

October 12, 2023 | 4:39 pm

BGS

Barclays analyst Andrew Lazar has maintained an Equal-Weight rating on B&G Foods (NYSE:BGS) and lowered the price target from $15 to $10.

Portfolio Pulse from Benzinga Newsdesk

October 12, 2023 | 4:37 pm

APPN

Barclays analyst Raimo Lenschow has maintained an Underweight rating on Appian (NASDAQ:APPN) and lowered the price target from $41 to $35.

Portfolio Pulse from Benzinga Newsdesk

October 12, 2023 | 4:36 pm

HOUS

Barclays analyst Steve Valiquette has maintained an Underweight rating on Anywhere Real Estate (NYSE:HOUS) and lowered the price target from $5 to $4.5.

Portfolio Pulse from Benzinga Newsdesk

October 12, 2023 | 4:34 pm

DVA

LLY

NVO

Novo Nordisk (NVO) halted trials for a potential kidney failure treatment due to early signs of efficacy. The trial's success could impact other drugmakers like Eli Lilly (LLY) and DaVita (DVA). The trial tested semaglutide, an ingredient in Novo's diabetes and weight-loss drugs. Eli Lilly, which makes a similar drug, saw a boost in shares, while DaVita, a dialysis firm, saw a slide in shares.

Portfolio Pulse from Adam Eckert

October 12, 2023 | 4:23 pm